Jiangsu Aidea Pharmaceutical Co., Ltd.

688488

CNE1000041S6

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
14.78 ^CNY	-1.66%		-3.40%	+18.15%

Apr. 25	Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Feb. 23	Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Jiangsu Aidea Pharmaceutical Co., Ltd. agreed to acquire 19.9646% stake in Nanjing Nanda Pharmaceutical Co., Ltd. from Jiangsu Sheng Feng Medical Technology Company Limited for CNY 86 million.

July 18, 2022

Jiangsu Aidea Pharmaceutical Co., Ltd. (SHSE:688488) agreed to acquire 19.9646% stake in Nanjing Nanda Pharmaceutical Co., Ltd. from Jiangsu Sheng Feng Medical Technology Company Limited for CNY 86 million on July 19, 2022. The board of Jiangsu Aidea Pharmaceutical Co., Ltd. (SHSE:688488) approved the transaction.

Latest news about Jiangsu Aidea Pharmaceutical Co., Ltd.

Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
Aidea Pharmaceutical, Subsidiaries Get Nod to Trial Anti-HIV Drug	Jan. 09	MT
Aidea Pharmaceutical Unit Scraps Transfer Deal with Lixin Biotechnology for Anti-Tumor Drug	Dec. 27	MT
Aidea Pharmaceutical's HIV Drug Granted Priority Review in China	Nov. 21	MT
China's Drug Regulator Selects Aidea Pharmaceutical's HIV Drug for Priority Review	Nov. 13	MT
Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Jiangsu Aidea Applies For 50 Million Yuan Bank Credit	23-09-01	MT
Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-21	CI
Aidea Pharma to Apply For 50 Million Yuan Bank Loan	23-06-19	MT
Jiangsu Aidea Pharma to Apply For 60 Million Yuan Bank Loan	23-05-25	MT
Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-24	CI
Jiangsu Aidea Pharma to Provide Services to China Medicines and Health Products in Three-Year Agreement	23-03-23	MT
Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Jiangsu Aidea Pharma Sees Larger Loss in 2022	23-01-25	MT
Jiangsu Aidea Pharma Registers HIV Tablets	23-01-06	MT
Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-25	CI
Jiangsu Aidea Pharmaceutical Co., Ltd. agreed to acquire 19.9646% stake in Nanjing Nanda Pharmaceutical Co., Ltd. from Jiangsu Sheng Feng Medical Technology Company Limited for CNY 86 million.	22-07-18	CI
Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI
Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-25	CI
Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-27	CI
Jiangsu Aidea Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-26	CI
Jiangsu Aidea Pharmaceutical Co., Ltd.(SHSE:688488) added to Shanghai Stock Exchange A Share Index	21-07-23	CI
Jiangsu Aidea Pharmaceutical Co., Ltd.(SHSE:688488) added to Shanghai Stock Exchange Composite Index	21-07-23	CI

Chart Jiangsu Aidea Pharmaceutical Co., Ltd.

Duration

Period

Chart Jiangsu Aidea Pharmaceutical Co., Ltd.

More charts

Company Profile

Jiangsu Aidea Pharmaceutical Co Ltd is a China-based company mainly engaged in the production and sales of human-source protein products. The Company is also engaged in the development and sales of some generic drugs, human immunodeficiency virus (HIV) diagnostic equipment and reagents. The Company is also engaged in the research and development of innovative drugs in anti-Acquired Immune Deficiency Syndrome (AIDS), anti-inflammatory and anti-tumor drugs fields. The Company's human-source protein products mainly include crude ulinastatin, crude urekline, crude urokinase and intermediates of ulinastatin. The Company mainly distributes its products within domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-22 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
JIANGSU AIDEA PHARMACEUTICAL CO., LTD.	+18.15%	859M
CSL LIMITED	-4.24%	86.85B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.16B
BIOGEN INC.	-16.60%	31.28B
UCB	+57.86%	25.27B
BIOMARIN PHARMACEUTICAL INC.	-15.37%	15.33B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.12%	11.96B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.56%	11.61B
SWEDISH ORPHAN BIOVITRUM AB	+6.89%	8.83B
INNOVENT BIOLOGICS, INC.	-10.53%	7.94B